Literature DB >> 16644672

Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass.

Jean Buteau1, Marianne L Spatz, Domenico Accili.   

Abstract

The glucoincretin hormone glucagon-like peptide-1 (GLP-1) increases pancreatic beta-cell proliferation and survival through sequential activation of the epidermal growth factor receptor (EGFR), phosphatidylinositol-3 kinase (PI 3-kinase), and Akt. We investigated the role of transcription factor FoxO1 in the proliferative and antiapoptotic actions of GLP-1 in beta-cells. GLP-1 inhibited FoxO1 through phosphorylation-dependent nuclear exclusion in pancreatic beta (INS832/13) cells. The effect of GLP-1 was suppressed by inhibitors of EGFR (AG1478) and PI 3-kinase (LY294002). In contrast, LY294002 but not AG1478 suppressed insulin-induced FoxO1 phosphorylation. Expression of constitutively nuclear FoxO1 in beta-cells prevented the proliferative and antiapoptotic actions of GLP-1 in cultured beta-cells and the increase in pancreatic beta-cell mass in response to Exendin4 in transgenic mice. Gene expression and chromatin immunoprecipitation assays demonstrated that GLP-1 increases pancreatic and duodenal homeobox gene-1 and Foxa2 expression and inhibits FoxO1 binding to both promoters. We propose that FoxO1 mediates the pleiotropic effects of the glucoincretin hormone on cell proliferation and survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16644672     DOI: 10.2337/db05-0825

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  58 in total

1.  Pancreatic diabetes manifests when beta cell area declines by approximately 65% in humans.

Authors:  J J Meier; T G K Breuer; R C Bonadonna; A Tannapfel; W Uhl; W E Schmidt; H Schrader; B A Menge
Journal:  Diabetologia       Date:  2012-05       Impact factor: 10.122

Review 2.  The role of gut hormones in glucose homeostasis.

Authors:  Daniel J Drucker
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

3.  Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).

Authors:  Rhonda D Wideman; Irene L Y Yu; Travis D Webber; C Bruce Verchere; James D Johnson; Anthony T Cheung; Timothy J Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

Review 4.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

5.  Protective Role of PPARdelta in Lipoapoptosis of Pancreatic β Cells.

Authors:  Yan Yang; Jiangong Ren; Yuzhen Tong; Xuejian Hu; Qingguo Lv; Nanwei Tong
Journal:  Lipids       Date:  2016-09-08       Impact factor: 1.880

Review 6.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

Review 7.  FoxO1, the transcriptional chief of staff of energy metabolism.

Authors:  Stavroula Kousteni
Journal:  Bone       Date:  2011-07-28       Impact factor: 4.398

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 9.  Paracrine signaling in islet function and survival.

Authors:  Sean M Hartig; Aaron R Cox
Journal:  J Mol Med (Berl)       Date:  2020-02-17       Impact factor: 4.599

10.  Glucagon-like peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-2/IGF-1 receptor autocrine loop.

Authors:  Marion Cornu; Jiang-Yan Yang; Evrim Jaccard; Carine Poussin; Christian Widmann; Bernard Thorens
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.